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Abstract 
Beyond guarding the cellular proteome the major stress inducible heat shock protein 
Hsp70 has been shown to interact with lipids. Non-cytosolic Hsp70 stabilizes 
membranes during stress challenges and, in pathophysiological states, facilitates 
endocytosis, counteracts apoptotic mechanisms, sustains survival pathways or 
represents a signal that can be recognized by the immune system. Disease-coupled 
lipid-associated functions of Hsp70 may be targeted via distinct subcellular 
localizations of Hsp70 itself or its specific interacting lipids. With a special focus on 
interacting lipids, here we discuss localization-dependent roles of the membrane-
bound Hsp70 in the context of its therapeutic potential, particularly in cancer and 
neurodegenerative diseases.  
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1. Introduction 
The stress-inducible heat shock protein 70, HSPA1A or Hsp70.1 (Hsp70 hereafter) 
(Hageman and Kampinga 2009) is expressed at low or undetectable levels in 
unstressed, healthy cells. Upon different stresses its expression is rapidly induced 
through mitogen-activated protein kinase/extracellular signal-regulated kinase 
(MAPK/ERK) and stress-activated protein kinase (SAPK) signaling cascades, which 
activate heat shock factors (HSFs) (Dubois and Bensaude 1993, Morimoto 1993, 
Adler, Schaffer et al. 1995, Xie and Huang 2003). Hsp70 restores the balance of the 
cell’s proteome by assisting in refolding of denatured proteins. Importantly, Hsp70 is 
frequently upregulated in disease states, including cancer. The tumor 
microenvironment, where cells are subjected to free radicals, acidosis, hypoxia and 
nutrient deprivation, and where high levels of mutant proteins are present, causes 
stressful conditions challenging cancer cells (Xie and Huang 2003). The resultant high 
levels of Hsp70 in various cancer cells (Santarosa, Favaro et al. 1997, Nanbu, Konishi 
et al. 1998) enhances cell growth, suppresses senescence and confers resistance to 
stress-induced apoptosis (Gabai, Yaglom et al. 2009).  
Hsp70 is commonly known as a cytosolic molecular chaperone that translocates to the 
nucleus upon stress conditions (Nollen, Salomons et al. 2001). However, it has been 
documented that Hsp70 also localizes to the luminal side of the endosomal-lysosomal 
system (Nylandsted, Gyrd-Hansen et al. 2004) and to the plasma membrane (Multhoff, 
Botzler et al. 1995, Multhoff, Botzler et al. 1997), as well as to the extracellular space 
(Asea, Kraeft et al. 2000) in pathophysiological states, such as cancer. Importantly, the 
unusual localization of Hsp70 is associated with a series of tumor specific functions 
such as counteracting lysosomal membrane permeabilization (LMP) and subsequent 
lysosome-dependent cell death (Kirkegaard, Roth et al. 2010) or immunomodulatory 
and invasion promoting roles of cell surface and extracellular Hsp70 (Gehrmann, 
Marienhagen et al. 2005). Given that normal cells do not show these specific features, 
Hsp70 unusually localized in endosomes, lysosomes and at the extracellular side 
represents therapeutically targetable functions.  
In fact, membrane association and lipid interactions have also been reported for 
several other members of the ubiquitous heat shock protein family, e.g. small heat 
shock proteins, Hsp60, Hsp70 and Hsp90, in different organisms (Torok, Horvath et al. 
1997, Torok, Goloubinoff et al. 2001, Tsvetkova, Horvath et al. 2002, Horvath, Multhoff 
et al. 2008, Zhang, Wang et al. 2018). As an indication of a functional interplay between 
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Hsps and membranes, expression of Hsps is controlled by the physical state of the 
membrane through activation of the Rac1-mediated heat shock response (Horvath, 
Glatz et al. 1998, Vigh, Maresca et al. 1998, Balogh, Horvath et al. 2005, Nagy, Balogi 
et al. 2007, Vigh, Horvath et al. 2007, Gungor, Gombos et al. 2014). Following specific 
lipid changes, membrane reorganization and interaction of Hsps with cellular 
membranes stabilize membrane structure and function during stress challenges 
(Balogi, Torok et al. 2005, Balogi, Cheregi et al. 2008, Balogh, Maulucci et al. 2011, 
Balogh, Peter et al. 2013). Membrane-controlled initiation and stopping of the heat 
shock response has led to the concept of regulating heat shock protein expression by 
modulating the membrane’s lipid phase through “membrane lipid therapy” (Torok, Crul 
et al. 2014, Escriba, Busquets et al. 2015). The heat shock protein co-inducer 
hydroximic acid derivatives, such as Bimoclomol and BGP-15, are small multi-target 
molecules that intercalate into membranes and stabilize their lipid rafts by modulating 
membrane composition and structure (Torok, Tsvetkova et al. 2003, Gombos, Crul et 
al. 2011). Several studies have shown beneficial effects of BGP-15 on various disease 
models (Crul, Toth et al. 2013). It is noted that such Hsp co-inducer compounds 
potentiate the response to a pre-existing stress without exhibiting effects in 
nonstressed environments. Dihydropyridine derivatives, another recently explored 
family of Hsp co-inducers, such as LA1011 and LA1044, improve the spatial learning 
and memory functions in wild type mice, and eliminate neurodegeneration by 
increasing dendritic spine density and reducing tau pathology and amyloid plaque 
formation in APPxPS1 double mutant mouse model of Alzheimer’s disease (Kasza, 
Hunya et al. 2016, Roe, Wahab et al. 2018). Recently it was shown that binding of 
these dihydropyridines to Hsp90 compromises Hsp90’s chaperone activity (Roe, 
Wahab et al. 2018), which consequently induces the heat shock response in diseased 
cells. Furthermore, xenohormetic plant compounds with a general beneficial effect on 
animals also induce Hsp expression, and therefore have been applied for the treatment 
of neurodevelopmental delay (Hooper, Hooper et al. 2010). Further modulators of Hsp 
expression with respect to neurological diseases have been described elsewhere 
(Penke, Bogar et al. 2018, Penke, Paragi et al. 2018). 
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2. Membrane crossing and post-translational modifications of HSP70 
Despite the high therapeutic potential of Hsp70 – membrane interaction, the 
mechanism by which Hsp70, lacking a leader sequence, is capable of crossing the 
endosomal-lysosomal or the plasma membrane is not well understood. In vitro studies 
with reconstituted protein-lipid systems have unraveled a specific interaction between 
Hsp70 and phosphatidylserine (PS) (Arispe, Doh et al. 2002, Lamprecht, Gehrmann et 
al. 2018) and proposed that Hsp70 oligomers generate pores in the cell membrane 
(Arispe, Doh et al. 2004). PS indeed confers a negative charge to the cytosolic leaflet 
of the plasma membrane and also to the endosomal membrane, allowing the 
recruitment of proteins with strong or moderate positive charges, respectively (Yeung, 
Gilbert et al. 2008). More recently, it has been shown that a cluster of positively 
charged Lys and Arg residues (R533 to K601/K597) anchor Hsc70/ Hsp70 to the 
endosomal membrane, which enables entry of Hsc70/Hsp70-cargo complexes to 
endosomes through microautophagy (Morozova, Clement et al. 2016). Interestingly, 
this lipid interacting region has been identified to be important for other functions as 
well. Hsp70 is composed of a nucleotide-binding domain (NBD) and a substrate-
binding domain (SBD), which are connected by a linker (Fig. 1A). The linker domain 
(aa 384-397) and a fraction (aa 557-641) of the helical lid subdomain (HLS) of SBD, 
which overlaps with the lipid interacting region (R533, R535, K569, K573, K589, K597 
of human Hsp70), are involved in oligomerization (Aprile, Dhulesia et al. 2013, 
Nimmervoll, Chtcheglova et al. 2015) (Fig. 1B). More specifically, Morgner et al. 
identified Lys rich regions throughout the whole molecule, but mostly in the SBD (K108-
K561/569), that direct Hsp70 monomers in an antiparallel orientation (Morgner, 
Schmidt et al. 2015). T504, K561, K568, K569 and K507, K512, K526 residues of the 
SBD in ATP and ADP bound state allow not only dimerization but also interaction with 
the co-chaperones Hsp40, Hsp90, HopGR and client proteins (Fig. 1C). Importantly, 
phosphorylation and acetylation of these residues stabilize protein-protein interactions 
and, therefore, they are likely to also affect lipid interactions of this region. Further, 
trimethylation of K561 of the Hsp70 family members by METTL21A methyltransferase 
alter the affinity of Hsp70 towards monomeric and fibrillar α-synuclein (Jakobsson, 
Moen et al. 2013), and phosphorylation and methylation of HLS residues including 
K561 and Y611 are necessary for proper ubiquitination by E3 ubiquitin ligase CHIP 
(Zhang, Amick et al. 2015). Hsp70 is ubiquitinated at 12 out of its 39 Lys residues 
including K561 (Soss, Rose et al. 2015). Hot-spots of phosphorylation in Ssa1, the 
 6 
yeast homologue of Hsp70, at T36-S38 and T492-S495-T499 are important for normal 
growth and survival (Beltrao, Albanese et al. 2012). A large number of multiple post-
translational modification sites point to a combinatorial code for a specific function 
(Cloutier and Coulombe 2013). Overlapping patterns of motives and post-translational 
modifications, in particular in the SBD, imply tight regulation of interrelated or interfering 
Hsp70 functions such as substrate or lipid binding (Fig. 1). To dissect the impact of 
post-translational modifications on Hsp70 localization and function necessitates further 
in-depth studies using subcellular fractions that can then be rendered to a specific 
function.  
 
  
 
Fig.1 Lipid interacting and post-translational modified regions of Hsp70 (A) Full length 
crystal structure and domains of Hsp70 shown for the prokaryotic Hsp70 DnaK (PDB: 2KHO). 
Hsp70 has an N-terminal nucleotide binding domain (NBD: pale brown), a short linker region 
(red) that couples to the substrate binding domain (SBD) consisting of a substrate-binding 
subdomain (SBSD: purple) and a helical lid subdomain (HLS: coral). (B) Residues of the 
“lysine-arginine cluster” interacting with the lipid phosphatydilserine (PS) (PDB: 4PO2 of the 
linker and SBD of human Hsp70). Positively charged R533, R535, K569, K573, K589, K597 
shown in red are proposed to specifically bind to PS at the cytoplasmic leaflet of endosomes, 
allowing Hsp70-cargo entry to endosomes via autophagy (Morozova, Clement et al. 2016). (C) 
Example residues that are post-translational modified (PTM) and functionally relevant (PDB: 
4PO2 of the linker and SBD of human Hsp70). Regions involved in oligomerization of Hsp70 
are shown in green. Further residues that are exposed to PTMs are shown (in red) as relevant 
for Hsp70 dimerization and client protein interaction (T504, K561, K568, K569 and K507, K512, 
K526), E3 Ub ligase CHIP interaction (K561, Y611). Different PTMs of K561 (in yellow) were 
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found to be important for substrate interaction, oligomerization, client and self-ubiquitination, 
cell growth and survival. For interpretation of the references to colour in this figure legend, the 
reader is referred to the web version of this article. 
 
3. HSP70 trafficking and tumor invasion 
Cell surface, endosomal, lysosomal and extracellular pools of Hsp70 are 
interconnected in a highly dynamic fashion (Fig. 2). Plasma membrane-bound Hsp70 
enters the endosomal route via clathrin dependent and independent mechanisms, and 
a fraction of internalized protein is recycled back to the surface. When excess Hsp70 
is present in the cell, Hsp70 is further trafficked to late endosomes and lysosomes 
(Juhasz, Thuenauer et al. 2013). Cytosolic Hsp70 may also enter the endo-lysosomal 
system via an autophagic mechanism as implicated above (Morozova, Clement et al. 
2016). Importantly, Hsp70 is resistant to proteolytic cleavage (and is, hence 
distinguishable from its cargos which are destined for lysosomal degradation) thus 
allowing it to exert its anti-apoptotic role. A large body of evidence describes Hsp70 
present in both membrane-bound and soluble forms in the endo-lysosomal system, 
which are released by multivesicular bodies (Bausero, Gastpar et al. 2005, Gastpar, 
Gehrmann et al. 2005, Lancaster and Febbraio 2005, Cordonnier, Chanteloup et al. 
2017) and secretory lysosomes (Mambula and Calderwood 2006, Juhasz, Thuenauer 
et al. 2013), respectively. These mechanisms not only supply plasma membrane 
bound Hsp70, but also result in a considerable amount of exosomal membrane-bound 
or soluble Hsp70 which has immunomodulatory potential.  
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Fig.2 Intracellular trafficking and 
secretion of Hsp70 Hsp70 (bucket symbol) 
is bound to the extracellular leaflet of the 
plasma membrane (PM). Surface Hsp70 is 
internalized to early endosomes (EE), a 
fraction of which is recycled back to the PM 
through sorting and recycling endosomes 
(SE, RE). Provided sufficient intracellular 
Hsp70, internalized Hsp70 is further 
trafficked to late endosomes/ multivesicular 
bodies (MVB), where BMP enriched 
intraluminal vesicles (ILV) are formed with 
Hsp70 attached to the membrane. Fusion of 
MVBs with the PM exposes Hsp70 at the cell 
surface and releases exosomes containing 
Hsp70. Hsp70 may further be targeted to 
lysosomes (L), which upon lysosomal 
exocytosis expose Hsp70 at the cell surface 
and release their soluble Hsp70 content to 
the extracellular space. Mechanisms of 
membrane crossing and supply of Hsp70 to 
the endolysosomal system are not known, 
but autophagy and direct membrane 
crossing mechanisms have been implicated.  
 
Upregulated expression levels of Hsp70 is a diagnostic measure in several cancers, 
indicating increased cancer cell proliferation, ‘clinical stage’, or ‘increased grade’ together 
with shorter overall survival (Lazaris, Theodoropoulos et al. 1995, Kaur, Srivastava et al. 
1998, Syrigos, Harrington et al. 2003, Juhasz, Lipp et al. 2013). Given the correlation 
between excess Hsp70 levels and its lysosomal, cell surface and extracellular 
appearance (Fig. 3), unusual localization of Hsp70 appears to be an attractive target for 
therapeutic interventions. These targets include but may not be limited to lysosomal 
membrane-bound Hsp70, which protects against lysosome-dependent cell death 
(Nylandsted, Gyrd-Hansen et al. 2004, Horvath and Vigh 2010, Kirkegaard, Roth et al. 
2010), and plasma membrane- bound Hsp70, which promotes invasion (Gehrmann, 
Marienhagen et al. 2005, Murakami, Kuhnel et al. 2015) and endocytosis (Nimmervoll, 
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Chtcheglova et al. 2015, Chtcheglova and Hinterdorfer 2018). These features that would 
give rise to survival benefit for cancer patients may provide unique possibilities to fight 
tumor progression and metastasis. Moreover, surface localized and extracellular Hsp70 
serve as potent stimuli for the innate immune system and can therefore be exploited as 
an effective adjuvant therapy (Multhoff, Pfister et al. 2000, Gong, Zhang et al. 2010). 
These targets and their therapeutic potential are detailed in the following sections.  
 
 
 
Fig.3 Model for excess Hsp70-mediated tumor invasion Low grade tumor cells with lower 
levels of intracellular Hsp70 (left side, bucket symbol used) also express low levels of Hsp70 in 
the endo-lysosomal system and at the cell surface, which correlate with a non-invasive 
phenotype. Contrary, high grade tumor cells often with high levels of intracellular Hsp70 (right 
side) express high levels of Hsp70 in the endo-lysosomal system and at the cell surface, as well 
as displaying an invasive phenotype. Anti-apoptotic effects of cytosolic or lysosomal Hsp70 and 
the tumor-promoting effect of surface Hsp70 are involved in facilitating tumor invasion as reviewed 
in (Juhasz, Lipp et al. 2013). Blue and red symbols correspond to basal (low level) and excess 
Hsp70, respectively. For trafficking routes refer to Fig. 2. MVB (late endosome, multivesicular 
body), L (lysosome), PM (plasma membrane). For interpretation of the references to colour in this 
figure legend, the reader is referred to the web version of this article. 
 
4. Plasma membrane bound and extracellular HSP70 
Global cell surface protein profiling of membranes of tumor and normal cells revealed a 
tumor-specific, plasma membrane localization of a variety of different Hsps (Multhoff, 
Botzler et al. 1995, Shin, Wang et al. 2003, Tsuneki, Maruyama et al. 2013). Although 
lacking a classical consensual transmembrane sequence, Hsp70 also has been found on 
the cell surface (Multhoff, Botzler et al. 1995, Chen, Tao et al. 2002, Shin, Wang et al. 
2003) and in the extracellular milieu of intact tumor cells (Pockley, Shepherd et al. 1998, 
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Pockley 2003, Calderwood, Mambula et al. 2007). Membrane localization of Hsps 
appears to be restricted to malignantly transformed cells (Multhoff, Botzler et al. 1995, 
Shin, Wang et al. 2003, Stangl, Gehrmann et al. 2011, Yang, Xu et al. 2015), 
bacterial/viral/fungal/parasite-infected cells and spermatogenic cells (Brown, Rixon et al. 
2005, Bottger, Multhoff et al. 2012, Silveira, Piffer et al. 2013). In normal cells, Hsp70 is 
only found inside the cell but not on the plasma membrane. Therapeutic interventions 
such as radiochemotherapy, Hsp90 inhibition and hyperthermia have been found to 
further increase the levels of cytosolic and membrane-bound Hsps (Multhoff, Botzler et 
al. 1995, Gehrmann, Marienhagen et al. 2005, Zunino and Ricci 2016) in tumor cells. The 
presence of Hsp70 in the extracellular milieu of viable cells (Guzhova, Kislyakova et al. 
2001, Triantafilou, Miyake et al. 2002, Barreto, Gonzalez et al. 2003) is currently 
explained by an alternative lysosomal/endosomal pathway (Fig. 2), which does not 
involve the classical ER-Golgi compartment (Mambula and Calderwood 2006). These 
findings concur with those from Asea and colleagues who demonstrated that drugs which 
perturb ER-Golgi transport, including monensin and brefeldin A, do not influence 
membrane expression and release of Hsp70 (Asea, Ara et al. 2001).  
 
5. Membrane anchorage of HSPS in tumor cell membranes 
Approximately 15 to 20 % of the total cellular Hsp70 is found on the plasma membrane 
of some tumor cells (Gehrmann, Liebisch et al. 2008). Since neither high-salt conditions 
nor changes in the extracellular pH affect the Hsp70 membrane expression density on 
tumor cells, it is unlikely that Hsp70 is bound to proteinous cell surface receptors 
(Theriault, Mambula et al. 2005). Already in 1989, Hightower and Guidon noted that 
Hsp71/Hsp73 could bind fatty acids and suggested possible direct interactions with 
membrane lipids (Hightower and Guidon 1989). Further on it has been proposed that 
Hsps accumulate in glycosphingolipid and cholesterol-rich microdomains (CRMs) 
(Uittenbogaard, Ying et al. 1998, Triantafilou, Miyake et al. 2002, Broquet, Thomas et al. 
2003, Zech, Ejsing et al. 2009). CRMs were originally defined as regions within the 
plasma membrane that are enriched in cholesterol, glycosphingolipids, 
glycosylphosphatidylinositol-anchored proteins and some other acylated proteins (van 
Engeland, Nieland et al. 1998, Kishimoto, Ishitsuka et al. 2016). As super-resolution cell 
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imaging techniques are now suitable for investigating membrane lipid domains (Sonnino 
and Prinetti 2013, Sezgin, Levental et al. 2017) these early findings should be revisited. 
A more recent effort has confirmed strong binding of Hsp70 to cholesterol and 
sphingomyelin domains in model membranes, and importantly high resolution atomic 
force microscopy revealed nano-domain size (up to 200 nm in diameter) of Hsp70 clusters 
on the cellular membrane (see Fig.4). These results may point to possible Hsp70-
membrane lipid platforms formed (Nimmervoll, Chtcheglova et al. 2015). “How these 
Hsp70 platforms are formed, and what is their role?” Glycosphingolipids that are enriched 
in tumor cell membranes, provide neoplastic and normal stem cell markers with 
immunogenic potential (Novak, Binnington et al. 2013). However, glycosphingolipid-
mediated immunoreactivity is often limited by a cholesterol-induced reorientation of 
glycosphingolipid head groups in a parallel rather than perpendicular conformation, which 
in turn hinders their recognition by the immune system (Novak, Binnington et al. 2013). 
Therefore, one could assume that cholesterol depletion by methyl-beta-cyclodextrin might 
improve immunogenicity of tumor cells. A comparative lipidomic analysis of the 
glycosphingolipid content revealed significantly greater amounts of globotriaosylceramide 
Gb3 (Nutikka and Lingwood 2004) in tumor cells with a high compared to a low Hsp70 
membrane expression. Gb3 is a receptor for Verotoxin (Lindberg, Brown et al. 1987, 
Lingwood, Law et al. 1987) and AB5-Shiga toxin, an enterotoxin produced by Shigella 
dysenteria and enterohemorrhagic Escherichia coli. It is frequently found in the plasma 
membrane of germinal center B cells and Burkitt`s lymphoma cells and solid tumors 
(Gregory, Tursz et al. 1987, Nudelman, Deutsch et al. 1987, Maloney and Lingwood 1994, 
Farkas-Himsley, Hill et al. 1995, Maloney, Binnington-Boyd et al. 1999, Johansson, 
Johansson et al. 2006) but it is not present in most normal cells. Staining of Gb3 and 
Hsp70 on the plasma membrane of Hsp70-positive tumor cells revealed their co-
localization. Moreover, cholesterol depletion results in a loss of Hsp70 from the plasma 
membrane of tumor cells (Gehrmann, Liebisch et al. 2008). Previous work by Lingwood 
et al. has demonstrated that Hsp70 also binds to 3`-sulfogalactolipids via its ATPase 
domain (NBD) (Fig. 1A) (Mamelak and Lingwood 2001). Based on binding patterns of 
antibodies that detect different epitopes of Hsp70 in the ATPase and the C-terminal 
substrate binding domain, the orientation of Hsp70 in Gb3 containing membrane domains 
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appears to support the above result. Together with the finding that recombinant Hsp70 
specifically interacts with artificial lipid vesicles containing Gb3, this supports the 
hypothesis that Gb3 might be one of the tumor-enriched lipid components that enables 
the integration of Hsp70 in the plasma membrane of tumor cells (Gehrmann, Liebisch et 
al. 2008). 
 
 
 
Fig.4 Hsp70 clustering at the tumor cell surface Hsp70 forms larger size of nano-domains in 
the cell membrane of tumor cells expressing higher level of intracellular Hsp70. (A) Model of 
plasma membrane-bound Hsp70, where blue and red symbols correspond to basal (low level) 
and excess Hsp70, respectively. (B) Topography, atomic force microscopy recognition and 
overlay images. Note that only red pixels above the recognition threshold (rec) are shown in 
overlay images. These areas are found Hsp70 positive (Nimmervoll, Chtcheglova et al. 2015). 
Data are displayed with courtesy of Dr. Lilia Chtcheglova and Prof. Peter Hinterdorfer, Johannes 
Kepler Univertity, Linz, Austria. For interpretation of the references to colour in this figure legend, 
the reader is referred to the web version of this article. 
 
Apart from the glycosphingolipid Gb3, Hsp70 has been found to interact with artificial lipid 
bilayers in the presence of phosphatidylserine (PS) (Arispe, Doh et al. 2002, Arispe, Doh 
et al. 2004). The group of DeMaio has shown that the interaction of Hsp70 with PS is 
largely based on the negative charge of phospholipids (Armijo, Okerblom et al. 2014). PS 
residing in liposomes enables the insertion of Hsp70 into the lipid bilayer and thereby can 
form higher molecular weight oligomers that facilitate ion conductance in artificial lipid 
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bilayers (Lopez, Cauvi et al. 2016). Assuming that PS serves as the natural binding 
partner for Hsp70 in vivo, a higher PS content would be expected in Hsp70 membrane-
positive tumor sublines. In non-stressed cells, PS is predominantly found on the inner 
membrane layer, whereas, upon stress PS can switch to the outer membrane leaflet, 
where it can be determined by a specific cell surface staining using the Ca2+-dependent 
phospholipid binding protein Annexin A5. PS on the outer membrane leaflet is considered 
as an early marker for apoptotic cell death in many cell types where it acts as an “eat-me” 
signal for macrophages (van den Eijnde, Boshart et al. 1998). However, in the case of 
tumor cells PS can also be present on the outer membrane leaflet of viable, therapy-
resistant, hypoxic cells (Schilling, Gehrmann et al. 2009). It appears that under non-
stressed conditions, Hsp70 predominantly resides in membrane clusters whereas 
following stress Hsp70 often co-localizes with PS outside these clusters. In line with this, 
atomic force microscopy combined with antigen specific recognition of surface Hsp70 
demonstrated that plasma membrane bound Hsp70 forms large clusters and rings 
potentially surrounding endocytic sites in the cell membrane at higher intracellular and 
cell surface Hsp70 concentrations (Fig. 4). Shown in both the cell membrane and 
reconstituted systems clustering was found to depend on the ability of Hsp70 to 
oligomerize, and larger nano-domains (above 70 nm in diameter) of surface Hsp70 
correlated with its ability to facilitate endocytosis in cancer cells (Nimmervoll, Chtcheglova 
et al. 2015, Chtcheglova and Hinterdorfer 2018).  
 
6. Immunological role and therapeutic exploitation of membrane-bound and 
extracellular HSP70 
Significant amounts of membrane-associated Hsp70 are often indicative of highly 
aggressive tumors, metastatic potential and resistance to therapy (Multhoff, Botzler et al. 
1997, Ciocca and Calderwood 2005, Murakami, Kuhnel et al. 2015). However, Hsps with 
molecular weights ranging from 70 to 90 kDa also elicit protective anti-tumor immune 
responses if expressed on the plasma membrane or in the extracellular milieu. Previous 
work of Multhoff and colleagues reported that in the presence of interleukin-2 (IL-2), 
plasma membrane-bound Hsp70 acts as a tumor-specific recognition structure for natural 
killer (NK) cells pre-activated with Hsp70 protein (Multhoff, Botzler et al. 1997, Multhoff, 
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Botzler et al. 1998, Multhoff, Mizzen et al. 1999) or a peptide derived thereof (TKD) 
(Multhoff, Pfister et al. 2001). In contrast, resting NK cells of tumor patients are unable to 
kill Hsp70 membrane-positive tumor cells. Since the induction of the cytolytic activity of 
NK cells with TKD/IL-2 is dose-dependent and saturable, it has been assumed that the 
stimulation of NK cells with Hsp70 peptide might be mediated via receptors. Blocking 
experiments revealed that the C-type lectin receptor CD94 in combination with the 
activatory co-receptor NKG2C as well as other activatory receptors such as the 
homodimeric receptor NKG2D and natural killer receptors (NKp30, NKp44, NKp46, 
NKp80) can act as mediators of the interaction of NK cells  with Hsp70 membrane-positive 
tumor cells (Borrego, Masilamani et al. 2006, Sullivan, Clements et al. 2007, Biassoni 
2009, Hromadnikova, Li et al. 2016). Following binding of these NK cell receptors to 
membrane-bound Hsp70, the production and release of the serine protease granzyme B 
and perforin is initiated which, in turn, results in apoptotic cell death of the tumor cell 
(Gross, Hansch et al. 2003, Gastpar, Gehrmann et al. 2005). Even in the absence of 
perforin, granzyme B has been found to interact with membrane-bound Hsp70 on tumor 
cells. Following binding and uptake of granzyme B into tumor cells via Hsp70-mediated 
endocytosis, apoptosis can thus be induced (Gehrmann, Stangl et al. 2012). It remains a 
matter of debate how granzyme B induces tumor cell apoptosis after endo-lysosomal 
transfer via an Hsp70 pathway.  
Depending on the Hsp profile of the lipid surface of actively released exosomes derived 
from tumor cells (Gastpar, Gehrmann et al. 2005, Lv, Wan et al. 2012) either stimulatory 
or inhibitory NK-mediated immune responses can be elicited. In the presence of 
immunogenic peptides that are chaperoned by extracellular Hsps also adaptive immune 
responses can be initiated following peptide cross-presentation via antigen presenting 
cells (Udono and Srivastava 1993, Srivastava 2002). Another mechanism whereby 
extracellular Hsp70 might be able to stimulate tumor cell death is the complex formation 
of the innate immunity protein Tag7 with Hsp70. It has been shown that the interaction of 
the Tag7-Hsp70 complex with TNFR1 triggers the activation of RIP1-kinase, an increase 
in intracellular concentration of Ca2+ and an activation of calpains, a family of Ca2+ 
dependent cytoplasmic cysteine proteases, which result in the permeabilization of 
lysosomal membranes (Yashin, Romanova et al. 2016). The lysosome-induced release 
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of cathepsins B and D can depolarize mitochondrial membranes and induce ROS 
production which eventually initiates tumor cell necroptosis (Yashin, Romanova et al. 
2016). In contrast to tumor cells, Hsp70 which is released by normal human monocytes 
in response to granulocyte monocyte-colony stimulating factor (GM-CSF) can prevent the 
formation of gap-junction intercellular communication between capillary cells and 
monocytes, and thus could affect inflammation and tumor growth (Thuringer, Berthenet 
et al. 2015). An anti-inflammatory cardioprotective effect could be shown by plasma 
exosomes expressing CD63, CD81 and Hsp70 derived from healthy donors (Vicencio, 
Yellon et al. 2015). This protective effect has been found to be dependent on Hsp70/Toll-
like receptor 4 (TLR4) interactions and an activation of kinases that stimulate Hsp27. In 
summary, depending on the source of the releasing cell type (tumor or normal cells) and 
the micromilieu (e.g. hypoxia (Rankin and Giaccia 2016)) Hsp-bearing exosomes can 
exert contradictory immunological responses.   
Patients with highly aggressive tumors have elevated levels of serum exosomes, which 
regulate cell-cell communication by transferring molecules such as cytosolic proteins 
(including Hsps), lipids, microRNAs and mRNAs (Peinado, Lavotshkin et al. 2011). Hsp70 
membrane-positive tumor cells secrete exosomes carrying Hsp70 on their membranes 
(Gastpar, Gehrmann et al. 2005). Extracellular as well as membrane-bound Hsp70 fulfil 
dual functions of mediating therapy resistance (Murakami, Kuhnel et al. 2015) and playing 
pivotal roles in anti-tumor immune responses (Multhoff, Botzler et al. 1997). Hsp70 
membrane-positive tumor cells have been found to be significantly more susceptible to 
the lysis of Hsp70-peptide and IL-2 activated NK cells as compared to their Hsp70 
membrane-negative counterparts (Multhoff, Botzler et al. 1995, Multhoff, Botzler et al. 
1997). At present the capacity of ex vivo TKD/IL-2-stimulated NK cells to kill autologous 
tumor cells is being tested in a clinical phase II trial in patients with non-small cell lung 
cancer after radiochemotherapy (Gunther, Ostheimer et al. 2015, Specht, Ahrens et al. 
2015). 
Furthermore, surface Hsp70 positive exosomes derived from tumor cells have been found 
to stimulate the migratory and cytolytic capacity of NK cells (Gastpar, Gehrmann et al. 
2005). In line with this finding, an intratumoral injection of recombinant Hsp70 into patients 
with glioblastoma has been shown to induce an increased cytolytic activity of NK cells 
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and a cytokine shift towards a T helper 1 (Th1)-mediated immune response in preclinical 
models (Shevtsov, Pozdnyakov et al. 2014) and a pilot study in human patients 
(Shevtsov, Komarova et al. 2014). Apart from recombinant Hsp70 protein that interacts 
with membrane Hsp70 through its oligomerization domain (Daugaard, Rohde et al. 2007), 
the serine protease granzyme B has been found to interact with membrane Hsp70 on 
tumor cells. Following binding and Hsp70-mediated recycling endosomes, granzyme B 
induces tumor-specific apoptosis via perforin-independent pathway (Gehrmann, Stangl 
et al. 2012). Regarding these findings EGFR targeting granzyme B which is 
overexpressed in NK cells has been found to enhance tumor apoptosis (Oberoi, 
Jabulowsky et al. 2013). The presence of perforin oligomers induces a rapid plasma 
membrane flip-flop of phospholipids that facilitate the translocation of granzyme B across 
plasma membrane bilayers (Metkar, Wang et al. 2011). HS-1 associated protein X-1 
(HAX-1), a protein that is involved in the maintenance of the mitochondrial membrane 
potential also serves as a target for granzyme B. After granzyme B-mediated HAX-1 
cleavage, the N-terminal part stimulates mitochondrial depolarization and subsequent 
lysosomal degradation (Chi, Zhu et al. 2010).  
 
7. HSP70 as a regulator of lysosomal lipid catabolism and membrane stability 
As discussed above, ample amounts of Hsp70 are found on the surface of cancer cells 
(Multhoff, Botzler et al. 1997, Hantschel, Pfister et al. 2000). Since high endocytic activity 
being a characteristic of cancer cells, it is, therefore, not surprising that their lysosomal 
membranes also contain this protein (Nylandsted, Jäättelä et al. 2004, Mambula and 
Calderwood 2006). More surprisingly and contrary to most other proteins ending up in the 
lysosomal lumen, Hsp70 is capable of resisting lysosomal hydrolases and of remaining 
functional in this hostile environment (Nylandsted, Gyrd-Hansen et al. 2004, Kirkegaard, 
Roth et al. 2010). The resistance to hydrolysis is likely due to the effective, pH-dependent 
anchorage of Hsp70 to the lysosomal membranes via its high-affinity binding to 
bis(monoacylglycero)phosphate (BMP, lysobisphosphatidic acid), an anionic 
phospholipid abundant in lysosomes (Kirkegaard, Roth et al. 2010). BMP accumulates 
predominantly in the membranes of intraluminal vesicles (ILV) of the endolysosomal 
system, and is critical for the formation of ILVs (Matsuo, Chevallier et al. 2004). 
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Fluorescence spectroscopy-based analyses of BMP-Hsp70 interactions suggest that 
BMP attaches to both the ATP- and the substrate-binding domain of Hsp70 in an 
extended conformation with acyl chains inserting into hydrophobic crevices within Hsp70 
(Mahalka, Kirkegaard et al. 2014). This anchorage is expected to cause a stringent 
orientation of Hsp70 on the membrane surface and to induce a transition of its substrate-
binding domain into an intermediate conformational state, which may be essential to 
retain substrate interactions within the hydrophobic bilayer interior. The functionality of 
lysosomal Hsp70 is supported by accumulating data showing that not only Hsp70 
expressed in cells, but also extracellularily added recombinant Hsp70 taken up by 
endocytosis and accumulating in lysosomes, regulates lysosomal lipid catabolism and 
lysosomal membrane integrity (Jäättelä, Wissing et al. 1998, Nylandsted, Jäättelä et al. 
2004, Hwang, Ryu et al. 2005, Gyrd-Hansen, Farkas et al. 2006, Bivik, Rosdahl et al. 
2007, Doulias, Kotoglou et al. 2007, Kirkegaard, Roth et al. 2010, Rammer, Groth-
Pedersen et al. 2010, Mena, Rodriguez et al. 2012, Ellegaard, Groth-Pedersen et al. 
2013, Zhu, Yoshimoto et al. 2014, Kirkegaard, Gray et al. 2016). As discussed below, 
these cytoprotective, lysosomal functions of Hsp70 open new possibilities to inhibit and 
promote cell death in the treatment of various degenerative diseases and cancer, 
respectively.  
 
8. Lysosomes and lysosome-related disorders 
Lysosomes are cytosolic vesicles that function as cellular recycling stations, where over 
50 acid hydrolases digest all major macromolecules of the cell to breakdown products 
available for metabolic reutilization (Saftig and Klumperman 2009). Additionally, they 
serve as major endocytic, Ca2+ signaling and more recently as metabolic hubs that sense 
the nutrient availability and translate it to appropriate signaling pathways (Lloyd-Evans, 
Morgan et al. 2008, Lloyd-Evans, Waller-Evans et al. 2010, Settembre, Fraldi et al. 2013, 
Bar-Peled and Sabatini 2014). Lysosomal membranes can be divided into the limiting 
membrane and any internal membranes of ILVs (Kolter and Sandhoff 2009). These differ 
significantly in their function and composition. The internal membranes are the sites of 
lipid degradation. As previously mentioned, they are characterized by high levels of an 
anionic phospholipid, BMP, whose negative charge serves as a docking site for positively 
 18 
charged domains of lysosomal lipases (e.g. acid sphingomyelinase) or their cofactors 
(e.g. saposin) (Kolter and Sandhoff 2009). At the same time, the limiting membrane 
serves as a barrier that inhibits lethal leakage of lysosomal hydrolases into the cytosol 
while controlling the proper exchange of ions and the export of metabolites (Saftig and 
Klumperman 2009). Heavily glycosylated luminal tails of lysosomal-associated 
membrane proteins (e.g. LAMP-1 and LAMP-2) form a protective glycocalyx shield to the 
inner face of the membrane (Eskelinen, Tanaka et al. 2003), and numerous channel-
forming proteins transport ions and metabolites across the lysosomal membrane (Lloyd-
Evans, Waller-Evans et al. 2010, Lloyd-Evans 2016). 
Deficiency or malfunction of various lysosomal hydrolases or their co-factors, transport 
proteins or membrane proteins leads to chronic, often lethal, lysosomal storage disorders 
that affect many organs, most critically brain (Futerman and van Meer 2004, Ballabio and 
Gieselmann 2009). In addition to the classic lysosomal storage disorders, that are the 
most common cause of childhood neurodegeneration (Lloyd-Evans and Haslett 2016), 
milder lysosomal dysfunction may contribute to pathologies of more common human 
diseases, such as neurodegeneration (Bourdenx and Dehay 2016, Lloyd-Evans and 
Haslett 2016, Stoka, Turk et al. 2016). Moreover, lysosomal hyper-activation has recently 
emerged as a hallmark of metastatic cancer (Kallunki, Olsen et al. 2013, Olson and Joyce 
2015, Hämälistö and Jäättelä 2016).  Although lysosomal storage disorders can be of 
mutation origin in over 50 different lysosomal or lysosome-regulating genes, also the 
accumulation of storage material and the resulting dysfunction of lysosomes results in 
overlapping tissue pathology and clinical symptoms, with cell death and neuronal loss 
being marked features in critically ill patients.  Loss of lysosomal membrane integrity and 
release of lysosomal hydrolases to the cytosol can be acutely lethal to cells. As the 
primary point of no return in a wide variety of cell death cascades (Boya and Kroemer 
2008, Kirkegaard and Jäättelä 2009, Aits and Jäättelä 2013, Appelqvist, Waster et al. 
2013), lysosomal leakage may, in turn, cause cellular and organ dysfunction developed 
during chronic lysosomal dysfunction. This view is supported by the demise of cells 
observed in samples from patients with some lysosomal storage disorders (Kirkegaard, 
Roth et al. 2010, Kollmann, Damme et al. 2012, Kollmann, Uusi-Rauva et al. 2013, 
Micsenyi, Sikora et al. 2013), and cancer cell death following lysosome-targeting 
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therapies (reviewed in (Kirkegaard and Jäättelä 2009, Groth-Pedersen and Jäättelä 
2013)). Notably, cancer cells either overexpressing Hsp70 or treated with recombinant 
Hsp70 are significantly protected against lysosomal leakage and subsequent cell death, 
whereas those depleted of Hsp70 undergo spontaneous lysosomal membrane 
permeabilization, or become more susceptible to lysosome-disruptive stimuli (Jäättelä, 
Wissing et al. 1992, Jäättelä, Wissing et al. 1998, Nylandsted, Jäättelä et al. 2004, 
Hwang, Ryu et al. 2005, Gyrd-Hansen, Farkas et al. 2006, Bivik, Rosdahl et al. 2007, 
Doulias, Kotoglou et al. 2007, Kirkegaard, Roth et al. 2010, Rammer, Groth-Pedersen et 
al. 2010, Mena, Rodriguez et al. 2012, Ellegaard, Groth-Pedersen et al. 2013, Petersen, 
Olsen et al. 2013, Subrizi, Toropainen et al. 2015). 
 
9. Lysosomal membrane integrity is regulated by HSP70 
Maintenance of the lysosomal membrane integrity is of utmost importance for cellular 
homeostasis and survival. Yet, our knowledge on the mechanisms regulating lysosomal 
membrane permeability is only beginning to emerge. Among the emerging lysosomal 
membrane destabilizers are certain lipids and reactive oxygen species (Aits and Jäättelä 
2013, Appelqvist, Waster et al. 2013), both of which can be regulated by Hsp70. 
Sphingomyelin, arachidonic acid and possibly high concentrations of sphingosine 
promote lysosomal leakage, cell death and enhanced pathology in cells and tissues from 
lysosomal storage disease patients (Kågedal, Zhao et al. 2001, Feldstein, Werneburg et 
al. 2004, Zhang, Yi et al. 2006, Kirkegaard, Roth et al. 2010, Ellegaard, Groth-Pedersen 
et al. 2013, Petersen, Olsen et al. 2013). The ability of Hsp70 to stabilize lysosomal 
membranes has been largely attributed to its ability to enhance sphingolipid catabolism 
in the lysosomes through its high-affinity binding to BMP (Kirkegaard, Roth et al. 2010, 
Petersen, Olsen et al. 2013, Kirkegaard, Gray et al. 2016). As discussed above, this 
anionic phospholipid is an essential cofactor for lysosomal sphingolipid catabolism (Kolter 
and Sandhoff 2005). Via its negative charge, it tethers several sphingolipid-degrading 
enzymes to the internal lysosomal membranes where their substrates are located, 
thereby increasing their activity and protecting them from lysosomal degradation. The 
high-affinity association of Hsp70 and BMP, which protects Hsp70 from lysosomal 
degradation as discussed above, also facilitates the BMP binding of sphingolipid-
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degrading enzymes and, in so doing, further enhances their activity and inhibits their 
degradation (Kirkegaard, Roth et al. 2010, Mahalka, Kirkegaard et al. 2014, Kirkegaard, 
Gray et al. 2016). The lysosomal membrane-stabilizing effect of Hsp70 may rely in 
particular on its enhancing effect on the enzyme acid sphingomyelinase that hydrolyses 
sphingomyelin to ceramide and phosphocholine (Fig. 5). Hsp70-induced conversion of 
ILV-sphingomyelin to ceramide counteracts lysosomal aggregation and membrane 
permeabilization, which are hallmarks of stress-induced cell death and may contribute to 
cellular pathophysiology in some lysosomal storage disorders (Kirkegaard, Roth et al. 
2010, Micsenyi, Sikora et al. 2013, Petersen, Olsen et al. 2013, Te Vruchte, Speak et al. 
2014). The mechanism by which accumulating ceramide stabilizes lysosomes remains 
largely unknown. Nevertheless, level of very long chain ceramide species (C24:0, C24:1, 
C24:2) was significantly increased in Hsp70 transgenic mouse embryonic fibroblast (MEF) 
cells as compared to their controls (Kirkegaard, Roth et al. 2010). While short to long 
chain ceramides are frequently considered as mediators of cellular death, very long chain 
ceramide species may protect membrane integrity and confer survival benefit on cells 
(Hartmann, Lucks et al. 2012, Stiban and Perera 2015, Rudd and Devaraj 2018). It is 
likely that ceramides accumulated in the lysosome eventually influence other cellular 
membranes, therefore affecting lysosomal stability indirectly as well (van Blitterswijk, van 
der Luit et al. 2003). If the plasma membrane integrity should be severely impaired 
lysosomal ASM, facilitated by Hsp70 may be also exposed to the cell surface, where 
ceramide-enriched platforms seal the membrane. This is achieved by conical shaped 
ceramides capable of inducing membrane invaginations hence facilitating vesicle budding 
and fission (Andrews, Almeida et al. 2014). Increased concentration of lysosomal 
ceramide counteracts aggregation of lysosomes with other intracellular vesicles and 
membranes, and perhaps strengthen the lysosomal limiting membranes by its ability to 
shape membranes (Heinrich, Wickel et al. 2000) Interestingly, Hsp70 could enhance also 
the catabolism of several less abundant sphingolipids (Kirkegaard, Gray et al. 2016), 
whose role in the maintenance of lysosomal membrane integrity remains to be studied. 
Of special interest is the enzyme galactosylceramidase, whose loss of activity results in 
accumulation of galactosylsphingosine (a.k.a. psychosine) that disrupts lysosomal pH 
(Folts, Scott-Hewitt et al. 2016), possibly destabilizing the lysosomal membranes by 
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interaction with the pH sensitive ion channel TDAG8 (Wang, Kon et al. 2004). Finally, it 
should be also noted that Hsp70-facilitated sphingomyelin degradation and concomitant 
ceramide accumulation allows a Niemann-Pick C2 (NPC2) mediated cholesterol egress 
from the lysosome (Infante, Wang et al. 2008, Oninla, Breiden et al. 2014), which is 
expected to affect membrane integrity and cell survival in multiple ways.  
 
In addition to regulating lysosomal lipid catabolism, Hsp70 may regulate lysosomal 
membrane stability by protecting the membranes from oxidative stress. Inside the 
lysosomes, iron and other chemically reactive metals (e.g. copper, zinc and cobalt) can 
generate reactive oxygen species through Fenton-type chemical reactions, which can 
lead to oxidization and destabilization of membrane lipids (Kurz, Eaton et al. 2010, 
Kiselyov, Colletti et al. 2011). Interestingly, one of the common pathologies in various 
lysosomal storage diseases is the marked elevation of oxidative stress providing a 
possible mechanistic clue to the loss of lysosomal integrity and cell death occurring in 
these diseases (Jeyakumar, Thomas et al. 2003, Shen 2008, Zampieri, Mellon et al. 2009, 
Vitner, Farfel-Becker et al. 2012). Importantly, the well documented protective effect of 
Hsp70 against oxidative stress is preserved inside the lysosomes. In the case of photo-
oxidation of acridine orange-loaded lysosomes, real-time high-resolution imaging has 
demonstrated that Hsp70 localized in the lysosomal lumen effectively protects lysosomal 
membranes and thereby mitigates their destabilization upon local oxidative stress 
(Kirkegaard, Roth et al. 2010). Furthermore, Hsp70 is cytoprotective in other lysosomal 
oxidative stress models, including age-related macular degeneration of retinal pigment 
epithelium and lysosomal iron accumulation (Nylandsted, Gyrd-Hansen et al. 2004, 
Doulias, Kotoglou et al. 2007, Subrizi, Toropainen et al. 2015). It remains to be studied, 
whether Hsp70 has a direct antioxidant effect or whether the protection of lysosomal 
membranes against oxidative stress is due to indirect effects, such as changes in the lipid 
composition of the membranes. 
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Fig.5 Hsp70-mediated preservation of lysosomal membrane integrity Lysosomal 
membranes, in particular those of intraluminal vesicles (ILVs) are enriched in 
bis(monoacyl)glycerophosphate (BMP) of inverted conical shape that allows high curvature 
membrane formation. (A) Negative charge of the head group of BMP recruits acid 
sphingomyelinase (ASM) as well as Hsp70 to the membrane surface. ASM converts 
sphingomyelin (SM) to membrane stabilizing ceramide (Cer), which is largely dependent on 
Hsp70 bound to the luminal side of ILVs. Hsp70 dependent activation of ASM and other lysosomal 
lipases eventually changes the lipid composition of all cellular membranes. (B) Hsp70 depletion 
generates lysosome instability, triggering in turn lysosomal membrane permeabilization (LMP)-
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mediated cell death. (C) Alternatively, cationic lysosomotropic drugs neutralize the negative 
charge of bis(monoacyl)glycerophosphate (BMP), that ASM and Hsp70 are anchored to, therefore 
causing lysosomal instability, LMP and cell death. PL: glycerophospholipid, Chol: cholesterol, 
double circle: limiting membrane   
 
10. Therapeutic exploitation of lysosomal HSP70 function 
After the initial discoveries of the role of Hsp70 in lysosomal membrane stability and 
lysosomal lipid catabolism (Nylandsted, Gyrd-Hansen et al. 2004, Kirkegaard, Roth et al. 
2010), a number of recent publications have reported improved lysosomal enzyme 
activities and lysosomal function through the induction of heat shock proteins in various 
lysosomal storage disorders (Mu, Ong et al. 2008, O'Leary and Igdoura 2012, Nakasone, 
Nakamura et al. 2014, Yang, Swallows et al. 2014, Zhu, Yoshimoto et al. 2014, 
Kirkegaard, Gray et al. 2016). As a consequence, the induction of the heat shock 
response is emerging as an attractive therapeutic approach to treat these devastating 
diseases. The power of this approach is supported by recent data showing that 
recombinant Hsp70 can reverse lysosomal pathology in primary fibroblasts from eight 
different lysosomal storage disorders and has significant therapeutic effects on both 
substrate accumulation and neurological manifestations in murine models of three of 
them, i.e. Fabry, Sandhoff and Niemann-Pick type C diseases (Kirkegaard, Gray et al. 
2016). Notably, these therapeutic effects of recombinant Hsp70 can be recapitulated by 
oral administration of arimoclomol, a small molecule co-inducer of heat shock proteins, 
currently in clinical trials for Niemann-Pick disease type C (Kirkegaard, Gray et al. 2016). 
It should be noted that the therapeutic effects of Hsp70 in lysosomal storage diseases 
are not confined to its direct effects in lysosomes, but are likely to depend also on the 
classic chaperone functions of Hsp70.  
Contrary to lysosomal storage disorders and degenerative disease, where increased 
lysosomal Hsp70 activity appears to have a beneficial effect, the inhibition of lysosomal 
Hsp70 function is emerging as an attractive approach to treat cancer. Whereas the direct 
inhibition of Hsp70 in the lysosomal lumen may be technically challenging, the inhibition 
of its target, acid sphingomyelinase, can be easily achieved. In fact, over a hundred 
commonly used, FDA-approved drugs are functional inhibitors of this enzyme (Kornhuber, 
Tripal et al. 2010). These drugs are characterized by a hydrophobic ring structure and a 
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hydrophilic side chain with a cationic amine group. In the acidic pH of lysosomes, the 
basic amine groups are protonated resulting in an up to 1000-fold accumulation (Trapp, 
Rosania et al. 2008). The incorporation of such cationic amphiphilic drugs into 
membranes in the lysosomal lumen neutralizes the negative membrane charge and 
inhibits the function of several lysosomal lipases, including acid sphingomyelinase 
(Kolzer, Werth et al. 2004). Thus, they have exactly the opposite effect to lysosomal 
Hsp70 (Fig. 5). Importantly, cancer cells are especially sensitive to the accumulation of 
sphingomyelin (Barcelo-Coblijn, Martin et al. 2011, Teres, Llado et al. 2012, Petersen, 
Olsen et al. 2013), which may explain why these functional inhibitors of acid 
sphingomyelinase display selective cytotoxicity towards transformed cells both in vitro 
and in various cancer models in mice (Groth-Pedersen, Ostenfeld et al. 2007, Ostenfeld, 
Høyer-Hansen et al. 2008, Jahchan, Dudley et al. 2013, Petersen, Olsen et al. 2013, 
Sukhai, Prabha et al. 2013, Shchors, Massaras et al. 2015, Ellegaard, Dehlendorff et al. 
2016). Their putative efficacy in cancer treatment is further supported by a recent 
pharmaco-epidemiological register-based cohort study showing a statistically significant 
association between cationic amphiphilic antihistamine use and reduced mortality among 
Danish cancer patients (Ellegaard, Dehlendorff et al. 2016).  
 
11. HSP70 disorder and lysosomal-mediated neuronal death 
Lysosome-dependent cell death is characterized by the destabilization of its limiting 
membrane (Fig. 5) followed by the leakage of cathepsins from the lysosomal lumen into 
the cytoplasm (Brunk, Zhang et al. 1995, Brunk, Dalen et al. 1997, Brunk and Svensson 
1999, Brunk, Neuzil et al. 2001, Aits and Jäättelä 2013, Lipton 2013, Gomez-Sintes, 
Ledesma et al. 2016). Using the monkey experimental systems of transient brain 
ischemia, Yamashima et al. (Yamashima, Saido et al. 1996, Yamashima, Kohda et al. 
1998, Yamashima 2000) formulated the ‘calpain-cathepsin hypothesis’ as a mechanism 
of programmed neuronal necrosis. They demonstrated that the lysosomal membrane of 
hippocampal CA1 neurons is disrupted by the activated μ-calpain after transient ischemia, 
which causes the release of lysosomal cathepsins B and L. Thereafter, the ‘calpain-
cathepsin hypothesis’ has been confirmed, using a variety of experimental paradigms 
from C. elegans to rodents (Syntichaki, Xu et al. 2002, Ceccariglia, D'Altocolle et al. 2011, 
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Villalpando Rodriguez and Torriglia 2013, Koriyama, Sugitani et al. 2014). The role of 
lysosomal enzyme cathepsins in initiation and execution of the necrotic cell death 
program has become clear (Boya and Kroemer 2008, Aits and Jäättelä 2013, Zhu, 
Yoshimoto et al. 2014). Moreover, the brain and neurons are regularly exposed to 
different kinds of acute and chronic environmental stresses. The brain contains high 
levels of polyunsaturated fatty acids and redox transition metal ions, especially iron. In 
spite of its high oxygen consumption, however, levels of lower molecular weight and 
enzymatic antioxidants are relatively low in the brain. Accordingly, the brain with poor 
antioxidant defense appears particularly susceptible to lipid peroxidation by reactive 
oxygen species (Chong, Li et al. 2005). Peroxidation of membrane lipids may show 
numerous effects such as increased membrane rigidity, decreased membrane-bound 
enzyme activity, altered membrane receptor activity, and altered membrane permeability. 
Therefore, it is not surprising that the role of lipid peroxidation has been widely 
investigated in the pathogenesis of a variety of neurodegenerative diseases including 
Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s 
disease, Down syndrome (Perluigi, Coccia et al. 2012).  
Importantly, lipid peroxidation yields a variety of bioactive products and one of the most 
extensively studied examples is hydroxynonenal (Dalleau, Baradat et al. 2013, Schaur, 
Siems et al. 2015). The most common source of hydroxynonenal is an endogenous one, 
when it is produced by peroxidation of membrane phospholipids or plasma low-density 
lipoproteins. Hydroxynonenal generation in the brain has been associated with exposure 
to drugs, ethanol or irradiation, and with ischemia or inflammation. In contrast, exogenous 
hydroxynonenal is generated during food processing, i.e., heating, especially deep-frying, 
of ω-6 vegetable oils (Fig. 6 A,B) (Dalleau, Baradat et al. 2013). Because of its chemical 
reactivity, hydroxynonenal can exert pleiotropic effects notably cell death. After the 
ischemia/ reperfusion sequence in myocardial infarction, accumulated reactive oxygen 
species promote generation of hydroxynonenal, which disrupts actin cytoskeleton, alters 
Ca2+ homeostasis, and triggers cardiomyocyte cell death (VanWinkle, Snuggs et al. 
1994). Hydroxynonenal induces signaling for apoptosis via both the Fas-mediated 
extrinsic and the p53-mediated intrinsic pathways (Chaudhary, Sharma et al. 2010, 
Dalleau, Baradat et al. 2013). Thus, hydroxynonenal can trigger β- cell apoptosis in the 
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pancreas, and induce glucose intolerance and type 2 diabetes (Mattson 2009). Since 
hydroxynonenal can impair Na+/Ca2+ pumps and glucose and glutamate transporters by 
modifying membranes, the resultant ionic and energetic disturbances cause neuronal cell 
death (Keller, Pang et al. 1997, Mark, Lovell et al. 1997). However, the detailed 
mechanism of how hydroxynonenal can lead to cell death has been controversial until 
recently. 
Accumulated data suggest dual roles of Hsp70 not only as a molecular chaperone for 
altered (misfolded/ aged/ damaged) proteins but also as a guardian of lysosomal integrity 
(Kirkegaard, Roth et al. 2010, Petersen and Kirkegaard 2010, Yamashima 2012, 
Yamashima 2013). Hsp70 contributes to lysosomal stabilization (Fig. 5) by binding to the 
endolysosomal anionic phospholipid BMP, a co-factor essential for sphingomyelin 
catabolism (Kirkegaard, Roth et al. 2010). Membranes of ILVs of the functioning 
lysosomes are characterized by abundant BMP (Kolter and Sandhoff 2009, Schulze, 
Kolter et al. 2009). Then, Hsp70-BMP binding enhances activity of acid 
sphingomyelinase, which mediates the sphingolipid degradation at the internal 
membrane in the acidic (pH4.5) compartment to generate ceramide (Linke, Wilkening et 
al. 2001, Linke, Wilkening et al. 2001, Kolter and Sandhoff 2005). Ceramide protects 
lysosomal membrane integrity as discussed above (Kirkegaard, Roth et al. 2010, 
Petersen and Kirkegaard 2010, Petersen, Kirkegaard et al. 2010) (Fig. 5A). Thus, in 
cases of Hsp70 depletion, not only failure of protein trafficking and degradation but also 
lysosomal destabilization or rupture may occur (Fig. 5B). In the monkey hippocampal CA1 
neurons after transient ischemia, Oikawa et al. (Oikawa, Yamada et al. 2009) previously 
found by proteomic analysis that Hsp70 can become an in vivo target of carbonylation by 
hydroxynonenal (Fig. 6C). Intriguingly, carbonylation of Hsp70 increased more than ten-
fold in the post-ischemic CA1 neurons, compared to the non-ischemic controls. 
Subsequently, in the in vitro experiments, Hsp70 being carbonylated by hydroxynonenal 
was found to become susceptible to cleavage by activated μ-calpain (Fig. 6D) (Sahara 
and Yamashima 2010). ‘Calpain-mediated cleavage of carbonylated Hsp70’ can lead to 
both autophagy failure and lysosomal destabilization with the resultant release of 
cathepsins and neuronal death (Yamashima and Oikawa 2009).  
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Fig.6 Generation of hydroxynonenal (HNE), HNE-mediated carbonylation and calpain-
mediated cleavage of carbonylated Hsp70 (A, B) Generation of hydroxynonenal (4-hydroxy-2-
nonenal) from ω-6 polyunsaturated fatty acids such as linoleic, arachidonic and gamma-linolenic 
acids. (C) Carbonylation of Hsp70 occurs at the key site Arg469 in post-ischemic CA1 neurons. 
(D) Time-dependent μ-calpain-mediated cleavage of carbonylated-Hsp70 by hydroxynonenal 
(HNE) in monkey CA1 tissue. For further details see text.  
 
Although neuronal death in Alzheimer’s disease has been thought to be caused by the 
initial cerebral accumulation of amyloid β for half a century, it still remains enigmatic 
because the underlying mechanism of Alzheimer neuronal death due to amyloid β still 
remains unknown. Thus, research of this disease is moving away from the simple 
assumption of linear causality as proposed in the ‘amyloid hypothesis’. Recently, 
hydroxynonenal has been shown to be involved in a great number of pathologies such as 
neurodegenerative diseases, metabolic diseases, and cancers (Mattson 2009). 
Yamashima recently put forward a perspective view that the causative substance for 
Alzheimer neuronal death is actually ω-6 vegetable oil-derived hydroxynonenal 
(Yamashima 2016). 
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Hsp70 is known to recycle altered proteins, stabilize lysosomal membranes and protect 
cells from diverse oxidative stresses. ‘Hydroxynonenal-induced Hsp70 carbonylation’ 
(Fig. 6C) followed by ‘calpain-mediated cleavage of carbonylated Hsp70’ (Fig. 6D) may 
be crucial for the execution of both ischemic and degenerative neuronal death. Calpain 
activation and Hsp70 disorder, combined together, at the lysosomal membranes may 
bring about programmed neuronal death by releasing hydrolytic cathepsin enzymes 
(Yamashima, Saido et al. 1996, Yamashima, Kohda et al. 1998, Yamashima 2000). The 
pathway of cerebral ischemia and/or oxidative stresses, either acute (in case of stroke) 
or chronic (in case of degeneration) could result the following sequence of μ-calpain 
activation → excessive intake of ω-6 vegetable oils → increase of hydroxynonenal in the 
brain → hydroxynonenal-mediated Hsp70 carbonylation → activated μ-calpain-mediated 
cleavage of carbonylated Hsp70 → lysosomal membrane destabilization → cathepsin 
release → breakdown of the cell constitutive proteins, which may in turn represent a 
central role not only for ischemic neuronal death (Yamashima 2000, Yamashima and 
Oikawa 2009, Yamashima 2012) but also for Alzheimer neuronal death (Yamashima 
2013, Yamashima 2016). 
A continuum of abnormalities of the lysosomal system can be identified in ischemic and 
Alzheimer neurons (Nixon, Wegiel et al. 2005, Lloyd-Evans and Haslett 2016). The 
common characteristic is that functional Hsp70 is indispensable for lysosomal autophagy 
that is crucial for the homeostasis of neurons. The control of protein turnover is particularly 
important in post-mitotic cells such as neurons, where accumulation of altered proteins 
may be highly detrimental to cell survival (Kopito 2000). Neurons must maintain large 
volumes of membrane and cytoplasm, and continually traffic autophagy-related garbage 
long distances from distal ends of dendrites and axons back to the cell body where 
lysosomes are most active for catabolite clearance (Lee, Sato et al. 2011). Hsp70 is the 
most structurally and functionally conserved chaperone that plays a principal role in the 
trafficking and degradation of altered proteins and their quality control for the 
cytoprotection of neurons under a number of different conditions (Yamashima 2016). 
Accordingly, in case of Hsp70 dysfunction, failure of lysosomal autophagy may occur, 
which leads to accumulation of autophagic vacuoles in both ischemic and Alzheimer 
neurons (Nixon, Wegiel et al. 2005). Since the proteotoxic stress in ischemia/reperfusion 
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during stroke is severe, neurons die within hours or days after the insult. On the contrary, 
the proteotoxic stress in Alzheimer’s diseases is extremely mild, and neurons can battle 
it for months or years, perhaps by raising pro-survival defenses such as Hsp70. Previous 
studies (Butterfield, Boyd-Kimball et al. 2003, Butterfield, Abdul et al. 2006, Butterfield, 
Reed et al. 2006, Butterfield, Reed et al. 2007, Sultana, Perluigi et al. 2010) indicated 
increased levels of protein oxidation in the Alzheimer brains, and suggested a possible 
involvement of hydroxynonenal-mediated protein carbonylation for the progression of 
Alzheimer’s disease. When sub-threshold levels of Hsp70 carbonylation are coupled with 
sub-threshold levels of calpain activation, for example, due to long-standing mild cerebral 
ischemia and/or amyloid β accumulation, programmed neuronal death becomes steadily 
significant year by year. Not only in cerebral ischemia but also in Alzheimer’s disease, 
‘calpain-mediated cleavage of carbonylated Hsp70' may cause lysosomal membrane 
rupture/destabilization, which leads to the release of cathepsins into the cytoplasm, which 
can  then trigger progressive neuronal death. Nowadays, researchers of Alzheimer’s 
disease are gradually but steadily moving away from the classical amyloid hypothesis, 
and speculate that another age-related, disease-promoting factor and/or substance 
probably interact with the core mechanisms of the disease. Accordingly, targeting Hsp70 
might be a promising strategy for both elucidating the mechanism of Alzheimer neuronal 
death as well as developing novel therapeutic agents for Alzheimer’s disease where 
defects in lysosomal proteolysis and lipid accumulation have been observed (Lee, 
McBrayer et al. 2015). 
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12. Concluding remarks 
It is now widely accepted that some of the heat shock protein molecular chaperones have 
additional biological functions over their basic role in cellular proteostasis, i.e. acting as 
'moonlighting proteins'. The moonlighting Hsp70 has been emerging an important 
therapeutic target. However, efforts targeting essential chaperone activity or the 
interacting complexes of Hsp70 with proteins have not yet resulted in excellent specific 
and efficient drug candidates of low toxicity (Lazarev, Sverchinsky et al. 2018, Taylor, 
Dunyak et al. 2018, Yaglom, Wang et al. 2018). Drug design is hampered by the facts 
that Hsps are highly conserved (Schlecht, Scholz et al. 2013) and that Hsp70, specifically 
Hsp70.1 has multiple functions. Hsp70 is in fact more than simply a cytosolic chaperone 
(Horvath, Multhoff et al. 2008, Juhasz, Lipp et al. 2013) and considered a major regulator 
of signaling pathways (Gabai, Yaglom et al. 2009, Sherman and Gabai 2015, Gabai, 
Yaglom et al. 2016). As reviewed here, non-cytosolic localization, membrane crossing 
and lipid interactions of Hsp70 are associated with membrane resistance, facilitation of 
endocytosis, counteracting apoptotic mechanisms and sustaining survival signaling at 
pathophysiological states. Unlike roles in the cytosol these unique functions may not only 
be targeted via Hsp70 itself or its interacting proteins, but also via specific lipids that either 
interact with or can be modulated by Hsp70. In order for rational drug design of 
membrane/ lipid-mediated Hsp70 functions, we need further mechanistic and structural 
studies of Hsp70 membrane interactions and lipid modulation.  
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